Prospects of Cell Therapy for Disorders of Myelin

被引：40

作者：

Ben-Hur, Tamir ^{[1
]}

Goldman, Steven A. ^{[2
,3
]}

机构：

[1] Hadassah Hebrew Univ Hosp, Agnes Ginges Ctr Human Neurogenet, Dept Neurol, IL-91120 Jerusalem, Israel

[2] Univ Rochester, Med Ctr, Dept Neurol, Div Cell & Gene Therapy, Rochester, NY 14642 USA

[3] Univ Rochester, Med Ctr, Dept Neurosurg, Div Cell & Gene Therapy, Rochester, NY 14642 USA

来源：

YEAR IN NEUROLOGY 2008 | 2008年 / 1142卷

关键词：

cell-based treatments; central nervous system; multiple sclerosis; myelin;

D O I：

10.1196/annals.1444.014

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Recent advances in stem cell biology have raised expectations that both diseases of, and injuries to, the central nervous system may be ameliorated by cell transplantation. In particular, cell therapy has been studied for inducing efficient remyelination in disorders of myelin, including both the largely pediatric disorders of myelin formation and maintenance and the acquired demyelinations of both children and adults. Potential cell-based treatments of two major groups of disorders include both delivery of myelinogenic replacements and mobilization of residual oligodendrocyte progenitor cells as a means of stimulating endogenous repair; the choice of modality is then predicated upon the disease target. In this review we consider the potential application of cell-based therapeutic strategies to disorders of myelin, highlighting the promises as well as the problems and potential perils of this treatment approach.

引用

页码：218 / 249

页数：32

共 303 条

[31] Normal timing of oligodendrocyte development from genetically engineered, lineage-selectable mouse ES cells [J].